Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Hepatol. Jan 27, 2024; 16(1): 41-53
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.41
Figure 4
Figure 4 Cumulative incidence and Survival probability of hepatocellular carcinoma between the direct-acting antiviral agents treatment group and the non-antiviral treatment group. A: Cumulative incidence of hepatocellular carcinoma (HCC) between direct-acting antiviral agents (DAAs) treatment group and non-antivial treatment group; B: Survival probability of HCC between new DAAs treatment group and non-antivial treatment group.